Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVOXAC vs ISOPTO CARPINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.
Treatment of dry mouth symptoms in patients with Sjögren's syndrome,Off-label: Management of radiation-induced xerostomia
FDA: For the treatment of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.,Off-label: Emergency reduction of intraocular pressure in acute angle-closure glaucoma, induction of miosis during ocular surgery, diagnosis of Adie's tonic pupil.
30 mg orally three times daily.
1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Terminal elimination half-life is approximately 1.4 hours in healthy adults; clinically, this short half-life necessitates frequent dosing for sustained ocular effect.
Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes N-oxidation and hydroxylation.
Primarily metabolized by plasma esterases via hydrolysis, with some hepatic metabolism. Half-life ~1-2 hours. Excreted renally as metabolites and unchanged drug.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is eliminated via urine within 24 hours, with about 20% as unchanged pilocarpine. Biliary/fecal elimination accounts for less than 5%.
Approximately 50-60% bound to plasma proteins, primarily albumin.
Approximately 30% bound to plasma proteins, mainly albumin.
Volume of distribution is approximately 6 L/kg, indicating extensive distribution into tissues beyond plasma water.
Approximately 0.5 L/kg, indicating distribution largely into extracellular fluid; clinically, not extensively distributed to tissues.
Oral bioavailability is approximately 30% due to extensive first-pass metabolism.
Ocular (topical): bioavailability is low due to nasolacrimal drainage and systemic absorption; exact % not well defined but systemic exposure is minimal with recommended ophthalmic dosing.
For GFR <30 m L/min: not recommended due to increased systemic exposure.
No dosage adjustment required for renal impairment; drug is minimally systemically absorbed and renally eliminated.
No adjustment required for mild to moderate hepatic impairment; not studied in severe impairment.
No dosage adjustment required for hepatic impairment; drug is minimally systemically absorbed and primarily metabolized locally.
Safety and efficacy not established; no recommended dose.
Not recommended for use in children due to lack of safety and efficacy data; use only if potential benefit outweighs risk.
No specific dose adjustment; monitor for increased anticholinergic effects due to age-related reduced clearance.
Use with caution in elderly patients due to increased risk of systemic anticholinergic effects (e.g., bradycardia, bronchospasm); consider lower concentration or frequency.
None.
None
Cardiovascular effects: May cause bradycardia, AV block, hypotension; use caution in patients with cardiovascular disease.,Pulmonary effects: Can exacerbate asthma, chronic bronchitis, or COPD due to increased bronchial secretions.,Ophthalmic effects: May impair night vision or cause visual disturbances; caution when driving at night.,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Caution in moderate to severe hepatic disease.,Potential for sweating and dehydration: Monitor fluid intake.,Drug interactions: Concomitant use with beta-blockers or other cholinergic agents may increase risk of bradycardia.
Risk of retinal detachment, especially in patients with pre-existing retinal disease or myopia.,May cause ciliary spasm, brow ache, and induced myopia.,Caution in patients with corneal abrasion or contact lens use due to miosis and accommodation effects.,Bronchospasm risk in patients with asthma or COPD.,Bradycardia, hypotension, and increased GI motility (use caution in peptic ulcer disease, urinary tract obstruction, or Parkinson's disease).,Systemic absorption can cause cholinergic toxicity.
Uncontrolled asthma,Narrow-angle glaucoma,Acute iritis,Hypersensitivity to cevimeline or any component,Concurrent use with certain anticholinergics (e.g., atropine) due to antagonistic effects
Hypersensitivity to pilocarpine or any component.,Acute iritis, acute anterior uveitis, or acute inflammatory conditions of the anterior chamber.,Narrow-angle glaucoma (unless considered for emergency treatment under specialist care).,Uncontrolled asthma, COPD, or other bronchospastic conditions.,Severe cardiovascular disease (bradycardia, hypotension, recent MI).,Gastrointestinal or urinary tract obstruction.,Concomitant use with other cholinergic agents due to additive toxicity.
No significant food interactions; may be taken with or without food. However, high-fat meals may delay absorption but not overall effect.
No known food interactions.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variations at doses 2-4 times the maximum recommended human dose. First trimester: Potential risk, use only if benefit justifies risk. Second trimester: Limited data, avoid unless necessary. Third trimester: No specific fetal risks identified, but monitor for maternal cholinergic effects.
Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.
Unknown if excreted in human breast milk. M/P ratio not available. Caution advised due to potential for cholinergic side effects in nursing infants. Consider discontinuing nursing or drug, taking into account importance of drug to mother.
Limited data; no M/P ratio available. Pilocarpine may suppress lactation via cholinergic effect. Use caution; monitor infant for cholinergic side effects.
No specific pharmacokinetic studies in pregnancy. Pregnancy may alter drug absorption and metabolism; however, no established dose adjustments. Start at lowest effective dose (30 mg three times daily) and titrate based on response and tolerability. Monitor for reduced efficacy or increased toxicity due to pregnancy-induced changes.
No established dose adjustments. Monitor IOP closely; pharmacokinetics may be altered due to increased plasma volume and renal clearance. Titrate to effect.
EVOXAC (cevimeline) is a cholinergic agonist used primarily for xerostomia in Sjögren's syndrome; a key pearl is to avoid concurrent use with other parasympathomimetics due to additive effects. Monitor for excessive sweating, bradycardia, and bronchospasm, especially in patients with asthma or COPD. Contraindicated in uncontrolled asthma, iritis, and angle-closure glaucoma. Dose reduction may be required in renal impairment.
Isopto Carpine (pilocarpine ophthalmic solution) is a miotic agent used for glaucoma and ocular conditions. It causes miosis and ciliary muscle contraction, reducing intraocular pressure. Onset of miosis is 10–30 minutes, lasting 4–8 hours. Use with caution in patients with retinal detachment, asthma, or bradycardia. Systemic absorption can cause sweating and salivation.
Take exactly as prescribed, usually three times daily with or without food.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause blurred vision or dizziness.,Report excessive sweating, abdominal cramps, slow heart rate, or difficulty breathing to your healthcare provider immediately.,Do not use with other medications that increase saliva or tear production without consulting your doctor.,Store at room temperature away from moisture and heat.
Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1–2 minutes after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait at least 15 minutes before reinserting.,May cause blurred vision, especially at night; avoid driving until vision clears.,Use caution in low-light conditions due to miosis.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVOXAC vs ISOPTO CARPINE, answered by our medical review team.
EVOXAC is a Cholinergic Agonist that works by Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.. ISOPTO CARPINE is a Ophthalmic Cholinergic Agonist that works by Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVOXAC and ISOPTO CARPINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVOXAC is: 30 mg orally three times daily.. The standard adult dose of ISOPTO CARPINE is: 1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVOXAC and ISOPTO CARPINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVOXAC is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variatio. ISOPTO CARPINE is classified as Category C. Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.